Immix Biopharma is a biopharmaceutical company developing a revolutionary one-time CAR-T therapy, NXC-201, designed to re-engineer the immune system to fight AL Amyloidosis. This therapy targets diseased cells, aiming to normalize disease within days and provide a durable response with minimal side effects, particularly for vulnerable patients with heart involvement. Immix Biopharma is focused on creating medicines that are both effective and safe, addressing the critical unmet need for relapsed/refractory AL amyloidosis patients.